Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 1226 - 1250 of 1455 in total
Experimental
Vet approved
ORE1001 has been used in trials studying the treatment of Mild to Moderate Ulcerative Colitis. It is an ACE2 inhibitor.
Investigational
AV-101 has been used in trials studying the treatment of Neuropathic Pain.
Investigational
Experimental
Experimental
Elsulfavirine is under investigation in clinical trial NCT03706898 (Study to Evaluate the Safety and PK of Elpida® in Healthy Subjects and Patients With Hepatic Impairment and to Assess the Impact of Food Intake and Drug-Drug Interactions With Other Antiviral Drugs).
Investigational
Mometasone is a corticosteroid not currently used in medical products. Mometasone furoate however, is still in use.
Experimental
Experimental
Illicit
Cinolazepam is a benzodiazepine derivative with anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant activity. It is not approved in Canada or America.
Experimental
Alvocidib is a synthetic flavonoid based on an extract from an Indian plant for the potential treatment of cancer. It works by inhibiting cyclin-dependent kinases, arresting cell division and causing apoptosis in non-small lung cancer cells.
Experimental
Investigational
GW-3965 is a liver X receptor ligand.
Experimental
Azimilide is an investigational class III anti-arrhythmic drug that blocks fast and slow components of the delayed rectifier cardiac potassium channels. It is not approved for use in any country, but is currently in clinical trials in the United States.
Investigational
Experimental
Pirlimycin hydrochloride is an antibiotic belonging to the lincosamide class. Often marketed as Pirsue, this drug is used to treat mastitis in cattle.
Vet approved
PF-03463275 has been used in trials studying the treatment of Schizophrenia and Cognitive Impairments Associated With Schizophrenia.
Investigational
Pf 06273340 is under investigation in clinical trial NCT01934738 (A Study to Evaluate Safety, Toleration and Time Course of Plasma Concentration of Multiple Oral Doses of PF-06273340 in Healthy Subjects of Two AgeGroups, Aged 18-55 Years (Group 1) and Aged 56-75 Years (Group 2)).
Investigational
Oglemilast has been investigated for the treatment of Pulmonary Disease, Chronic Obstructive.
Investigational
Displaying drugs 1226 - 1250 of 1455 in total